Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $19 to $21.
Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $19 to $21.